(Q38168905)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308581%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308581%20AND%20SRC:MED&resulttype=core&format=json

eradication of infectious diseases

2 March 2020

main subject

1 reference

1 reference

poliovirus

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308581%20AND%20SRC:MED&resulttype=core&format=json

Radboud J Duintjer Tebbens

2 March 2020

series ordinal

2

object named as

Radboud J Duintjer Tebbens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308581%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

4 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308581%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308581%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308581%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308581%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

221-234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308581%20AND%20SRC:MED&resulttype=core&format=json

Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Preeradication vaccine policy options for poliovirus infection and disease control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Poliovirus vaccination options for achieving eradication and securing the endgame

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Modeling poliovirus risks and the legacy of polio eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Modeling population immunity to support efforts to end the transmission of live polioviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Expert review on poliovirus immunity and transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Oral and inactivated poliovirus vaccines in the newborn: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Vaccine policy changes and epidemiology of poliomyelitis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Single versus multi-dose vaccine vials: an economic computational model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

The costs of future polio risk management policies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Systematic review of the effects of pertussis vaccines in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION *

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563

A case for developing antiviral drugs against polio

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.864563